What does Cullinan Therapeutics, Inc. do?
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T…
What is Cullinan Therapeutics, Inc.'s P/E and P/B ratio?
Cullinan Therapeutics, Inc. has a P/E ratio of -4.8 and a P/B ratio of 2.85.
What is Cullinan Therapeutics, Inc.'s debt-to-equity ratio?
Cullinan Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does Cullinan Therapeutics, Inc. owe compared with what it owns?
Cullinan Therapeutics, Inc. owes $0.12 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Cullinan Therapeutics, Inc.'s Positivity rank?
Cullinan Therapeutics, Inc. is ranked #4,500 of 6,774 companies globally and #2,264 of 4,000 in United States on PositoAI, with a Positivity Score of 19,364.
Does Cullinan Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Cullinan Therapeutics, Inc..
Where can I read the latest news about Cullinan Therapeutics, Inc.?
Recent headlines about Cullinan Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Cullinan Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Cullinan Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.